Clinical Trial Update: (Bicalutamide) Casodex vs Placebo in Non-metastatic Early Prostate Cancer [Phase 3]

View source ↗

Summary

A completed Phase 3 clinical trial comparing bicalutamide (Casodex) to placebo in men with non-metastatic early prostate cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• Casodex (bicalutamide)

Snippet

Sponsor: AstraZeneca | Conditions: Non-Metastatic Prostate Cancer | Phase 3 | Status: COMPLETED